Genocea raises $35 million for T cell vaccine pipeline
This article was originally published in Scrip
Executive Summary
Genocea Biosciences, which is developing T cell-based vaccines, has closed a $35 million series B round of financing. New investors Johnson & Johnson Development Corporation, Skyline Ventures and MP Healthcare Venture Management joined existing investors Polaris Venture Partners, Lux Capital Management, SR One, Cycad Group, Auriga Partners and Morningside Ventures.